Rhumbline Advisers Arcus Biosciences, Inc. Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

A detailed history of Rhumbline Advisers transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 172,673 shares of RCUS stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

172,673

Previous 171,338 0.78%

Holding current value

$2.53 Million

Previous $3.27 Million 0.37%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$14.83 - $20.18 $19,798 - $26,940	1,335 Added 0.78%	172,673 $3.26 Million
Q4 2023 Feb 08, 2024	BUY	$13.43 - $19.63 $19,997 - $29,229	1,489 Added 0.88%	171,338 $3.27 Million
Q3 2023 Nov 09, 2023	BUY	$17.62 - $23.54 $71,590 - $95,643	4,063 Added 2.45%	169,849 $3.05 Million
Q2 2023 Aug 08, 2023	SELL	$16.97 - $22.03 $5,006 - $6,498	-295 Reduced 0.18%	165,786 $3.37 Million
Q1 2023 May 11, 2023	BUY	$15.96 - $23.15 $48,582 - $70,468	3,044 Added 1.87%	166,081 $3.03 Million

Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $92,235 - $167,194	4,682 Added 2.96%	163,037 $3.37 Million
Q3 2022 Nov 10, 2022	BUY	$23.23 - $30.07 $292,883 - $379,122	12,608 Added 8.65%	158,355 $4.14 Million
Q2 2022 Aug 11, 2022	BUY	$17.23 - $37.73 $1.46 Million - $3.2 Million	84,927 Added 139.64%	145,747 $3.69 Million
Q1 2022 May 12, 2022	SELL	$28.92 - $41.83 $132,945 - $192,292	-4,597 Reduced 7.03%	60,820 $1.92 Million
Q4 2021 Feb 10, 2022	SELL	$31.38 - $48.47 $2,698 - $4,168	-86 Reduced 0.13%	65,417 $2.65 Million
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $673 - $942	-25 Reduced 0.04%	65,503 $2.28 Million
Q2 2021 Aug 05, 2021	BUY	$22.75 - $35.77 $403,926 - $635,096	17,755 Added 37.17%	65,528 $1.8 Million
Q1 2021 May 06, 2021	SELL	$26.16 - $41.39 $93,862 - $148,507	-3,588 Reduced 6.99%	47,773 $1.34 Million
Q4 2020 Feb 10, 2021	BUY	$17.0 - $32.36 $87,142 - $165,877	5,126 Added 11.09%	51,361 $1.33 Million
Q3 2020 Nov 12, 2020	SELL	$17.14 - $25.47 $46,055 - $68,437	-2,687 Reduced 5.49%	46,235 $792,000
Q2 2020 Aug 13, 2020	SELL	$13.97 - $36.56 $75,940 - $198,740	-5,436 Reduced 10.0%	48,922 $1.21 Million
Q1 2020 May 06, 2020	BUY	$8.78 - $19.28 $45,173 - $99,195	5,145 Added 10.45%	54,358 $754,000
Q4 2019 Feb 05, 2020	BUY	$7.33 - $10.79 $2,594 - $3,819	354 Added 0.72%	49,213 $497,000
Q3 2019 Oct 23, 2019	BUY	$6.44 - $10.18 $30,010 - $47,438	4,660 Added 10.54%	48,859 $445,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $34,000 - $62,404	4,664 Added 11.8%	44,199 $351,000
Q1 2019 May 01, 2019	SELL	$8.95 - $12.49 $2,747 - $3,834	-307 Reduced 0.77%	39,535 $494,000
Q4 2018 Jan 31, 2019	BUY	$9.74 - $14.5 $388,061 - $577,709	39,842 New	39,842 $429,000

Others Institutions Holding RCUS

# of Institutions

186

Shares Held

49.2M

Call Options Held

204K

Put Options Held

149K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Arcus Biosciences, Inc. Transaction History